Top

memo - Magazine of European Medical Oncology

Published in:

Open Access 01-09-2018 | short review

Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?

Authors: Matthias Pinter, MD PhD, Wolfgang Sieghart

Published in: memo - Magazine of European Medical Oncology | Issue 3/2018

Summary

Liver resection, transplantation, and local ablation are potential curative treatment options but can only be offered to patients with early stage hepatocellular carcinoma (HCC). Patients with macrovascular tumor invasion and extrahepatic metastases are candidates for palliative systemic therapies. Achieving radiological complete response can be associated with long-term remission and excellent outcome. However, despite recent advancements in the medical treatment of advanced stage HCC, complete remission with available systemic treatment options still remains a rare event. This review summarizes data on radiological complete response to systemic therapies and discusses issues that may complicate the goal of achieving cure in advanced stage HCC.

Pinter M, Hucke F, Zielonke N, Trauner M, Sieghart W, Peck-Radosavljevic M. Epidemiological trends of hepatocellular carcinoma in Austria. Dig Dis. 2014;32(6):664–9. https://doi.org/10.1159/000367983.CrossRefPubMed

Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. Esmo Open. 2016;1(2):e42. https://doi.org/10.1136/esmoopen-2016-000042.CrossRefPubMedPubMedCentral

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Ca Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRefPubMed

European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019.CrossRef

European Association For The Study Of The L,, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43. https://doi.org/10.1016/j.jhep.2011.12.001.CrossRef

Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1.CrossRefPubMed

Zhu AX, Kang YK, Yen CJ, et al. REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol 2018;36(suppl): abstr 4003.

Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial. J Clin Oncol. 2018;36(suppl 4S): abstr 207.

El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502. https://doi.org/10.1016/S0140-6736(17)31046-2.CrossRefPubMedPubMedCentral

10.

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–16.CrossRefPubMed

11.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

12.

Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35(3):421–30.CrossRefPubMed

13.

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. https://doi.org/10.1055/s-0030-1247132.CrossRefPubMed

14.

Rimola J, Diaz-Gonzalez A, Darnell A, et al. Complete response under sorafenib in patients with hepatocellular carcinoma: relationship with dermatologic adverse events. Hepatology. 2017; https://doi.org/10.1002/hep.29515.CrossRef

15.

Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e52. https://doi.org/10.1016/S1470-2045(17)30074-8.CrossRefPubMedPubMedCentral

16.

Easson EC, Russell MH. Cure of Hodgkin’s disease. Br Med J. 1963;1(5347):1704–7.CrossRefPubMedPubMedCentral

17.

Miller K, Abraham JH, Rhodes L, Roberts R. Use of the word “cure” in oncology. J Oncol Pract. 2013;9(4):e136–e40. https://doi.org/10.1200/JOP.2012.000806.CrossRefPubMedPubMedCentral

18.

Hucke F, Sieghart W, Schoniger-Hekele M, Peck-Radosavljevic M, Muller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria—is there a need for a structured screening program? Wien Klin Wochenschr. 2011;123(17–18):542–51. https://doi.org/10.1007/s00508-011-0033-9.CrossRefPubMed

19.

Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):938–45. https://doi.org/10.1016/j.cgh.2007.02.039.CrossRefPubMed

20.

Li DK, Ren Y, Fierer DS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology. 2018;67(6):2244–2253. https://doi.org/10.1002/hep.29707.CrossRefPubMed

21.

Colombo M, Iavarone M. Role of antiviral treatment for HCC prevention. Best Pract Res Clin Gastroenterol. 2014;28(5):771–81. https://doi.org/10.1016/j.bpg.2014.07.017.CrossRefPubMed

22.

D’Ambrosio R, Corte DC, Colombo M. Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy. Int J Mol Sci. 2015;16(8):19698–712. https://doi.org/10.3390/ijms160819698.CrossRefPubMedPubMedCentral

23.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):P1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2.PubMedCrossRef

24.

Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol. 2013;58(4):724–9. https://doi.org/10.1016/j.jhep.2012.11.009.CrossRefPubMed

25.

Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9. https://doi.org/10.1056/NEJM199603143341104.CrossRefPubMed

26.

Kummar S, Gutierrez M, Doroshow JH, Murgo AJ. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol. 2006;62(1):15–26. https://doi.org/10.1111/j.1365-2125.2006.02713.x.CrossRefPubMedPubMedCentral

27.

Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33(2):172–9. https://doi.org/10.1200/JCO.2013.54.3298.CrossRefPubMed

28.

Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.CrossRefPubMed

29.

Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067–75. https://doi.org/10.1200/JCO.2012.45.8372.CrossRefPubMed

30.

Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31(28):3517–24. https://doi.org/10.1200/JCO.2012.48.4410.CrossRefPubMed

31.

Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013;31(28):3509–16. https://doi.org/10.1200/JCO.2012.47.3009.CrossRefPubMed

32.

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857.CrossRefPubMed

33.

Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014;312(1):57–67. https://doi.org/10.1001/jama.2014.7189.CrossRefPubMed

34.

Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–70. https://doi.org/10.1016/S1470-2045(15)00050-9.CrossRefPubMed

35.

Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–66. https://doi.org/10.1200/JCO.2013.53.7746.CrossRefPubMed

36.

Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.CrossRefPubMed

37.

Kobayashi S, Ueshima K, Moriguchi M, et al. JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c‑Met high hepatocellular carcinoma. Ann Oncol. 2017;28(suppl_5): abstr 6190.

38.

Rimassa L, Assenat E, Peck-Radosavljevic M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19(5):682–93. https://doi.org/10.1016/S1470-2045(18)30146-3.CrossRefPubMed

39.

Abbadessa G, Rimassa L, Pressiani T, Carrillo-Infante C, Cucchi E, Santoro A. Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. World J Gastroenterol. 2011;17(19):2450–3. https://doi.org/10.3748/wjg.v17.i19.2450.CrossRefPubMedPubMedCentral

40.

Ahn SY, Lee HS, Kweon YO, Tak WY, Park SY. Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy. Dig Dis Sci. 2013;58(5):1428–32. https://doi.org/10.1007/s10620-012-2522-8.CrossRefPubMed

41.

Azmi AN, Chan WK, Goh KL. Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy. J Dig Dis. 2015;16(9):537–40. https://doi.org/10.1111/1751-2980.12270.CrossRefPubMed

42.

Gerardi AM, Stoppino LP, Liso A, Macarini L, Landriscina M. Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma. Oncol Lett. 2013;5(3):975–7. https://doi.org/10.3892/ol.2013.1131.CrossRefPubMedPubMedCentral

43.

Hagihara A, Teranishi Y, Kawamura E, et al. A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma. Intern Med. 2013;52(14):1589–92.CrossRefPubMed

44.

Inuzuka T, Nishikawa H, Sekikawa A, et al. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. Oncology. 2011;81(Suppl 1):152–7. https://doi.org/10.1159/000333279.CrossRefPubMed

45.

Katafuchi E, Takami Y, Wada Y, et al. Long-term maintenance of complete response after Sorafenib treatment for multiple lung metastases from hepatocellular carcinoma. Case Rep Gastroenterol. 2015;9(2):285–90. https://doi.org/10.1159/000438746.CrossRefPubMedPubMedCentral

46.

Kee KM, Hung CH, Wang JH, Lu SN. Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib. Onco Targets Ther. 2014;7:829–34. https://doi.org/10.2147/OTT.S61740.PubMedPubMedCentralCrossRef

47.

Kim TS, Kim JH, Kim BH, et al. Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review. Clin Mol Hepatol. 2017;23(4):340–6. https://doi.org/10.3350/cmh.2016.0070.CrossRefPubMedPubMedCentral

48.

Kudo M, Ueshima K. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology. 2010;78(Suppl 1):154–66. https://doi.org/10.1159/000315245.CrossRefPubMed

49.

Maida M, Macaluso FS, Valenza F, Virdone R. Complete and sustained off-therapy response to Sorafenib in advanced Hepatocellular carcinoma. J Gastrointestin Liver Dis. 2016;25(2):253–5. https://doi.org/10.15403/jgld.2014.1121.252.off.PubMedCrossRef

50.

Mizukami H, Kagawa T, Arase Y, et al. Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma. Case Rep Oncol. 2012;5(2):380–4. https://doi.org/10.1159/000341259.CrossRefPubMedPubMedCentral

51.

Moroni M, Zanlorenzi L. Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma. Future Oncol. 2013;9(8):1231–7. https://doi.org/10.2217/fon.13.86.CrossRefPubMed

52.

Sacco R, Bargellini I, Gianluigi G, et al. Complete response for advanced liver cancer during sorafenib therapy: case report. Bmc Gastroenterol. 2011;11:4. https://doi.org/10.1186/1471-230X-11-4.CrossRefPubMedPubMedCentral

53.

Shinoda M, Kishida N, Itano O, et al. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature. World J Surg Oncol. 2015;13:144. https://doi.org/10.1186/s12957-015-0559-9.CrossRefPubMedPubMedCentral

54.

Shiozawa K, Watanabe M, Ikehara T, et al. Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: a case report. Oncol Lett. 2014;7(1):50–2. https://doi.org/10.3892/ol.2013.1664.CrossRefPubMed

55.

Simao A, Silva R, Correia L, Caseiro Alves F, Carvalho A, Nascimento Costa JM. Advanced stage Hepatocellular carcinoma with multiple metastasis and vascular thrombosis: a case of complete response to Sorafenib. Acta Med Port. 2016;29(2):139–42. https://doi.org/10.20344/amp.6799.CrossRefPubMed

56.

So BJ, Bekaii-Saab T, Bloomston MA, Patel T. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol. 2008;1:18. https://doi.org/10.1186/1756-8722-1-18.CrossRefPubMedPubMedCentral

57.

Waidmann O, Peveling-Oberhag J, Eichler K, Schulze F, Vermehren J. To treat or not to treat—Successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenib. Z Gastroenterol. 2017;55(6):564–8. https://doi.org/10.1055/s-0042-118232.CrossRefPubMed

58.

Wang SX, Byrnes A, Verma S, Pancoast JR, Rixe O. Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. Target Oncol. 2010;5(1):59–63. https://doi.org/10.1007/s11523-010-0133-x.CrossRefPubMed

59.

Shiba S, Okusaka T, Ikeda M, Saito H, Ichida T. Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. Hepatol Res. 2014;44(13):1268–76. https://doi.org/10.1111/hepr.12297.CrossRefPubMed

60.

Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014;61(2):318–24. https://doi.org/10.1016/j.jhep.2014.03.030.CrossRefPubMed

61.

Park JG. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. Clin Mol Hepatol. 2015;21(3):287–94. https://doi.org/10.3350/cmh.2015.21.3.287.CrossRefPubMedPubMedCentral

62.

Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis. 2014;34(4):444–55. https://doi.org/10.1055/s-0034-1394143.CrossRefPubMed

63.

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.CrossRefPubMedPubMedCentral

64.

Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774.CrossRefPubMed

65.

Crocenzi TS, El-Khoueiry AB, Yau TC, et al. Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. J Clin Oncol. 2017;35(suppl): abstr 4013.

66.

Zhu A, Finn R, Cattan S, et al. Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update. J Clin Oncol. 2018;36(suppl): abstr 4020.

67.

Ikeda M, Sung MW, Kudo M, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2018;36(suppl): abstr 4076.

68.

Stein S, Pishvaian MJ, Lee MS, et al. Safety and clinical activity of 1 L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). J Clin Oncol. 2018;36(suppl): abstr 4074.

69.

Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatology. 2013;59(1):81–8CrossRef

70.

Wainberg ZA, Segal NH, Jaeger D, et al. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC). J Clin Oncol. 2017;35(suppl): abstr 4071.

71.

Kelley RK, Abou-Alfa GK, Bendell JC, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. J Clin Oncol. 2017;35(suppl): abstr 4073.

72.

Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatology. 2017;66(3):545–551CrossRef

73.

El-Khoueiry AB, Melero I, Yau TC, et al. Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. J Clin Oncol. 2018;36(suppl 4S): abstr 475.

74.

Chen Y, Huang Y, Reiberger T, et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 2014;59(4):1435–47. https://doi.org/10.1002/hep.26790.CrossRefPubMed

75.

Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605–22. https://doi.org/10.1016/j.ccell.2014.10.006.CrossRefPubMedPubMedCentral

76.

Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med. 2017;9:eaan5616. https://doi.org/10.1126/scitranslmed.aan5616.PubMedPubMedCentralCrossRef

77.

Greten TF, Sangro B. Targets for immunotherapy of liver cancer. J Hepatol. 2017; https://doi.org/10.1016/j.jhep.2017.09.007.CrossRefPubMedPubMedCentral

Title: Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?
Authors: Matthias Pinter, MD PhD
Wolfgang Sieghart
Publication date: 01-09-2018
Publisher: Springer Vienna
Published in: memo - Magazine of European Medical Oncology / Issue 3/2018
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-018-0431-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 3/2018

Role of complement in the pathogenesis of thrombotic microangiopathies

Nonmalignant hematology

Cure in metastatic disease

Thrombotic thrombocytopenic purpura

Cure in metastatic breast cancer

Still making progress

Keynote webinar | Spotlight on antibody–drug conjugates in cancer